Pfizer to Supply Global Fund Up to 6 Million Paxlovid Treatment Courses

By Will Feuer

Pfizer Inc. said it has agreed to supply up to six million treatment courses of Paxlovid, its oral treatment for Covid-19, to the Global Fund for low-and-middle-income countries, based on Pfizer's tiered pricing.

The Global Fund says it is a movement focused on defeating HIV, tuberculosis and malaria. It raises and invests $4 billion a year to fight the world's deadliest infectious diseases, according to its website. The organization's Covid-19 response mechanism has awarded $4.3 billion to 131 countries since April 2020 to mitigate the impact of the pandemic on programs to fight HIV, TB and malaria, its website says.

Pfizer said the Global Fund's Covid-19 response mechanism has been the main channel for providing grant support to low- and middle-income countries to purchase Covid tests, treatments and personal protective equipment. The company said Paxlovid treatment courses would be available for procurement through the program, subject to local regulatory approval or authorization of the treatment.

Pfizer said it expects supply to be available starting this year, with doses of Paxlovid offered based on the company's tiered pricing approach, in which low- and lower-middle-income countries will pay a not-for-profit price. The company didn't disclose other financial details of the deal.

Write to Will Feuer at [e-mail]

(END) Dow Jones Newswires

September 22, 2022 07:23 ET (11:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.